IL2 and cancer: In order to focus on the combination therapy of the two drugs, we consider in the model only the following variables: cancer cells (C), dendritic cells (DCs), CD4+ and CD8+ T cells, GM-CSF, PD-1, PD-L1, PD-1-PD-L1 complex, and cytokines IL-12 and IL-2.